CARGO Therapeutics, Inc. Common Stock (CRGX) 

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Show less

Over the last 12 months, insiders at CARGO Therapeutics, Inc. Common Stock have bought $0 and sold $294,684 worth of CARGO Therapeutics, Inc. Common Stock stock.

On average, over the past 5 years, insiders at CARGO Therapeutics, Inc. Common Stock have bought $10M and sold $294,684 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 666,666 shares for transaction amount of $10M was made by PERCEPTIVE ADVISORS LLC (Former 10% Owner) on 2023‑11‑14.